Novel Biomarkers to Distinguish between Type 3c versus Type 2 Diabetes Mellitus by Untargeted Metabolomics

Pancreatology ◽  
2020 ◽  
Vol 20 ◽  
pp. S98
Author(s):  
O. Caba ◽  
C. Jiménez-Luna ◽  
A. Martín-Blázquez ◽  
C. Diéguez-Castillo ◽  
Pérez Del Palacio J. ◽  
...  
Metabolites ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 423
Author(s):  
Cristina Jimenez-Luna ◽  
Ariadna Martin-Blazquez ◽  
Carmelo Dieguez-Castillo ◽  
Caridad Diaz ◽  
Jose Luis Martin-Ruiz ◽  
...  

Pancreatogenic diabetes mellitus (T3cDM) is a highly frequent complication of pancreatic disease, especially chronic pancreatitis, and it is often misdiagnosed as type 2 diabetes mellitus (T2DM). A correct diagnosis allows the appropriate treatment of these patients, improving their quality of life, and various technologies have been employed over recent years to search for specific biomarkers of each disease. The main aim of this metabolomic project was to find differential metabolites between T3cDM and T2DM. Reverse-phase liquid chromatography coupled to high-resolution mass spectrometry was performed in serum samples from patients with T3cDM and T2DM. Multivariate Principal Component and Partial Least Squares-Discriminant analyses were employed to evaluate between-group variations. Univariate and multivariate analyses were used to identify potential candidates and the area under the receiver-operating characteristic (ROC) curve was calculated to evaluate their diagnostic value. A panel of five differential metabolites obtained an area under the ROC curve of 0.946. In this study, we demonstrate the usefulness of untargeted metabolomics for the differential diagnosis between T3cDM and T2DM and propose a panel of five metabolites that appear altered in the comparison between patients with these diseases.


2019 ◽  
Vol 4 (7) ◽  
pp. S418
Author(s):  
G. Da Silva Jr. ◽  
A.K. M. Neri ◽  
G. C. Meneses ◽  
S. Fraser ◽  
A. M.C. Martins ◽  
...  

Author(s):  
Joep van der Leeuw ◽  
Joline W. J. Beulens ◽  
Susan van Dieren ◽  
Casper G. Schalkwijk ◽  
Jan F. C. Glatz ◽  
...  

Author(s):  
Lei Wan ◽  
Xinying Song ◽  
Baoqing Zhu

IntroductionType 2 diabetes mellitus (T2DM) is a major kind of diabetes mellitus. This study aimed to analyze the regulatory effect of long noncoding RNA NBR2 on pancreatic  cell function and the related mechanisms, and to analyze the clinical significance of abnormal NBR2 expression in patients with T2DM.Material and methodsThe expression levels of NBR2 and microRNA-19a-3p (miR-19a-3p) were measured using quantitative Real-Time PCR. The glucose-stimulated insulin secretion was measured using ELISA kit, and cell proliferation was examined using Cell Counting Kit-8 (CCK-8) assay. A dual-luciferase reporter assay was used to confirm the relationship between NBR2 and miR-19a-3p. The diagnostic values of NBR2, miR-19a-3p and NBR2 combined with miR-19a-3p were assessed by receiver operating characteristic (ROC) curves.ResultsThe insulin secretion and proliferation of INS-1 cells were inhibited by NBR2 overexpression, and were promoted by NBR2 knockdown. MiR-19a-3p, which was inhibited by NBR2 overexpression, directly mediated the regulatory effects of NBR2 on INS-1 cell function. Increased serum NBR2 level and decreased serum miR-19a-3p level were found in T2DM patients, and a negative correlation was found between NBR2 and miR-19a-3p. The fasting plasma glucose of T2DM patients was positively correlated with serum NBR2 and negatively correlated with serum miR-19a-3p. Both serum NBR2 and miR-19a-3p had certain diagnostic accuracy, whereas, the combined detection of the serum NBR2 and miR-19a-3p showed more considerable diagnostic accuracy.ConclusionsOur findings indicated that NBR2/miR-19a-3p axis regulates pancreatic β cell function, while may be novel biomarkers for the diagnosis of T2DM.


Sign in / Sign up

Export Citation Format

Share Document